Which has higher earnings & valuation, TLX or ELAN?

Telix Pharmaceuticals has higher earnings, but lower revenue than Elanco Animal Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.18 -$7.12M N/A N/A Elanco Animal Health $4.72B 2.80 -$232M -$0.50 N/A

Does the media refer more to TLX or ELAN?

In the previous week, Elanco Animal Health had 4 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 10 mentions for Elanco Animal Health and 6 mentions for Telix Pharmaceuticals. Elanco Animal Health's average media sentiment score of 0.73 beat Telix Pharmaceuticals' score of 0.45 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, TLX or AXSM?

Telix Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.18 -$7.12M N/A N/A Axsome Therapeutics $638.50M 17.57 -$183.17M -$3.73 N/A

Does the media refer more to TLX or AXSM?

In the previous week, Axsome Therapeutics had 5 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 11 mentions for Axsome Therapeutics and 6 mentions for Telix Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 0.92 beat Telix Pharmaceuticals' score of 0.45 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Axsome Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, TLX or ARWR?

Arrowhead Pharmaceuticals has lower revenue, but higher earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.18 -$7.12M N/A N/A Arrowhead Pharmaceuticals $622.01M 19.17 -$1.63M -$2.15 N/A

Which has stronger earnings & valuation, TLX or ABVX?

Telix Pharmaceuticals has higher revenue and earnings than Abivax. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.18 -$7.12M N/A N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is TLX or ABVX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Abivax N/A -99.02% -70.26%

Does the media favor TLX or ABVX?

In the previous week, Abivax had 7 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 13 mentions for Abivax and 6 mentions for Telix Pharmaceuticals. Abivax's average media sentiment score of 1.47 beat Telix Pharmaceuticals' score of 0.45 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Abivax 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, TLX or KRYS?

Krystal Biotech has lower revenue, but higher earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.18 -$7.12M N/A N/A Krystal Biotech $389.13M 25.84 $204.83M $7.48 45.60

Does the media refer more to TLX or KRYS?

In the previous week, Krystal Biotech had 8 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 14 mentions for Krystal Biotech and 6 mentions for Telix Pharmaceuticals. Krystal Biotech's average media sentiment score of 1.32 beat Telix Pharmaceuticals' score of 0.45 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Telix Pharmaceuticals (TLX) Competitors

$9.89 -0.17 (-1.69%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$9.88 -0.01 (-0.10%)

As of 07/31/2026 07:34 PM Eastern

Compare

TLX vs. ELAN, AXSM, ARWR, ABVX, and KRYS

Should you buy Telix Pharmaceuticals stock or one of its competitors? MarketBeat compares Telix Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Telix Pharmaceuticals include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Arrowhead Pharmaceuticals (ARWR), Abivax (ABVX), and Krystal Biotech (KRYS).

How does Telix Pharmaceuticals compare to Elanco Animal Health?

Telix Pharmaceuticals (NASDAQ:TLX) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Telix Pharmaceuticals has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

Telix Pharmaceuticals has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Elanco Animal Health	-4.95%	7.42%	3.66%

Telix Pharmaceuticals currently has a consensus price target of $20.40, suggesting a potential upside of 106.27%. Elanco Animal Health has a consensus price target of $28.73, suggesting a potential upside of 8.72%. Given Telix Pharmaceuticals' higher probable upside, research analysts plainly believe Telix Pharmaceuticals is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Telix Pharmaceuticals has higher earnings, but lower revenue than Elanco Animal Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.18	-$7.12M	N/A	N/A
Elanco Animal Health	$4.72B	2.80	-$232M	-$0.50	N/A

97.5% of Elanco Animal Health shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Elanco Animal Health had 4 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 10 mentions for Elanco Animal Health and 6 mentions for Telix Pharmaceuticals. Elanco Animal Health's average media sentiment score of 0.73 beat Telix Pharmaceuticals' score of 0.45 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Elanco Animal Health beats Telix Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Axsome Therapeutics?

Telix Pharmaceuticals (NASDAQ:TLX) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Telix Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.18	-$7.12M	N/A	N/A
Axsome Therapeutics	$638.50M	17.57	-$183.17M	-$3.73	N/A

In the previous week, Axsome Therapeutics had 5 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 11 mentions for Axsome Therapeutics and 6 mentions for Telix Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 0.92 beat Telix Pharmaceuticals' score of 0.45 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axsome Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Telix Pharmaceuticals has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Telix Pharmaceuticals' return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Telix Pharmaceuticals currently has a consensus target price of $20.40, indicating a potential upside of 106.27%. Axsome Therapeutics has a consensus target price of $261.29, indicating a potential upside of 19.86%. Given Telix Pharmaceuticals' higher possible upside, equities analysts clearly believe Telix Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Axsome Therapeutics beats Telix Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Arrowhead Pharmaceuticals has lower revenue, but higher earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.18	-$7.12M	N/A	N/A
Arrowhead Pharmaceuticals	$622.01M	19.17	-$1.63M	-$2.15	N/A

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Telix Pharmaceuticals presently has a consensus target price of $20.40, indicating a potential upside of 106.27%. Arrowhead Pharmaceuticals has a consensus target price of $96.92, indicating a potential upside of 14.49%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Telix Pharmaceuticals is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Telix Pharmaceuticals has a beta of -0.31, meaning that its stock price is 131% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

In the previous week, Arrowhead Pharmaceuticals had 18 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 24 mentions for Arrowhead Pharmaceuticals and 6 mentions for Telix Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.00 beat Telix Pharmaceuticals' score of 0.45 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Telix Pharmaceuticals' return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Summary

Arrowhead Pharmaceuticals beats Telix Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Abivax?

Telix Pharmaceuticals (NASDAQ:TLX) and Abivax (NASDAQ:ABVX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Telix Pharmaceuticals' return on equity of 0.00% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Abivax	N/A	-99.02%	-70.26%

47.9% of Abivax shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Telix Pharmaceuticals has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market. Comparatively, Abivax has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

In the previous week, Abivax had 7 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 13 mentions for Abivax and 6 mentions for Telix Pharmaceuticals. Abivax's average media sentiment score of 1.47 beat Telix Pharmaceuticals' score of 0.45 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abivax	11 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals presently has a consensus price target of $20.40, indicating a potential upside of 106.27%. Abivax has a consensus price target of $156.50, indicating a potential upside of 25.28%. Given Telix Pharmaceuticals' higher possible upside, equities research analysts clearly believe Telix Pharmaceuticals is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Telix Pharmaceuticals has higher revenue and earnings than Abivax.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.18	-$7.12M	N/A	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Summary

Telix Pharmaceuticals and Abivax tied by winning 6 of the 12 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Krystal Biotech?

Telix Pharmaceuticals (NASDAQ:TLX) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Telix Pharmaceuticals currently has a consensus price target of $20.40, indicating a potential upside of 106.27%. Krystal Biotech has a consensus price target of $360.67, indicating a potential upside of 5.73%. Given Telix Pharmaceuticals' higher possible upside, equities analysts plainly believe Telix Pharmaceuticals is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Krystal Biotech has a net margin of 53.92% compared to Telix Pharmaceuticals' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Krystal Biotech	53.92%	19.25%	17.62%

Krystal Biotech has lower revenue, but higher earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.18	-$7.12M	N/A	N/A
Krystal Biotech	$389.13M	25.84	$204.83M	$7.48	45.60

In the previous week, Krystal Biotech had 8 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 14 mentions for Krystal Biotech and 6 mentions for Telix Pharmaceuticals. Krystal Biotech's average media sentiment score of 1.32 beat Telix Pharmaceuticals' score of 0.45 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Krystal Biotech	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

86.3% of Krystal Biotech shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Krystal Biotech beats Telix Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Get Telix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLX vs. The Competition

Export

Metric	Telix Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.42B	$3.61B	$7.24B	$12.30B
Dividend Yield	N/A	3.78%	2.59%	9.45%
P/E Ratio	N/A	7.71	280.89	24.66
Price / Sales	4.18	1,260.87	641.00	110.52
Price / Cash	238.60	93.43	71.02	59.62
Price / Book	8.04	16.81	11.09	5.90
Net Income	-$7.12M	-$12.44M	$3.50B	$336.31M
7 Day Performance	-3.23%	-1.44%	-0.25%	0.09%
1 Month Performance	-16.47%	-7.53%	-2.98%	-5.67%
1 Year Performance	-24.21%	48.77%	61.96%	18.79%

Telix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLX Telix Pharmaceuticals	4.1171 of 5 stars	$9.89 -1.7%	$20.40 +106.3%	-27.2%	$3.42B	$803.79M	N/A	1,184	News Coverage Short Interest Increase Analyst Revision
ELAN Elanco Animal Health	2.912 of 5 stars	$25.92 +2.0%	$28.73 +10.8%	+93.0%	$12.94B	$4.89B	N/A	9,400	Upcoming Earnings
AXSM Axsome Therapeutics	3.3375 of 5 stars	$238.29 0.0%	$261.48 +9.7%	+115.0%	$12.25B	$638.50M	N/A	380	Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.1061 of 5 stars	$83.18 -2.8%	$95.08 +14.3%	+435.8%	$11.73B	$829.45M	N/A	400	News Coverage Upcoming Earnings Analyst Forecast Analyst Revision
ABVX Abivax	3.9471 of 5 stars	$122.47 -4.3%	$156.50 +27.8%	+74.1%	$10.67B	N/A	N/A	61	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLX) was last updated on 8/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telix Pharmaceuticals (TLX) Competitors

TLX vs. ELAN, AXSM, ARWR, ABVX, and KRYS

How does Telix Pharmaceuticals compare to Elanco Animal Health?

Summary

How does Telix Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Telix Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Summary

How does Telix Pharmaceuticals compare to Abivax?

Summary

How does Telix Pharmaceuticals compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telix Pharmaceuticals (TLX) Competitors

TLX vs. ELAN, AXSM, ARWR, ABVX, and KRYS

How does Telix Pharmaceuticals compare to Elanco Animal Health?

Which has more risk & volatility, TLX or ELAN?

Is TLX or ELAN more profitable?

Do analysts prefer TLX or ELAN?

Which has higher earnings & valuation, TLX or ELAN?

Do institutionals & insiders hold more shares of TLX or ELAN?

Does the media refer more to TLX or ELAN?

Summary

How does Telix Pharmaceuticals compare to Axsome Therapeutics?

Which has better valuation & earnings, TLX or AXSM?

Does the media refer more to TLX or AXSM?

Which has more volatility and risk, TLX or AXSM?

Is TLX or AXSM more profitable?

Do institutionals & insiders have more ownership in TLX or AXSM?

Do analysts prefer TLX or AXSM?

Summary

How does Telix Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Which has higher valuation & earnings, TLX or ARWR?

Do institutionals & insiders have more ownership in TLX or ARWR?

Do analysts recommend TLX or ARWR?

Which has more risk & volatility, TLX or ARWR?

Does the media refer more to TLX or ARWR?

Is TLX or ARWR more profitable?

Summary

How does Telix Pharmaceuticals compare to Abivax?

Is TLX or ABVX more profitable?

Do insiders & institutionals believe in TLX or ABVX?

Which has more volatility & risk, TLX or ABVX?

Does the media favor TLX or ABVX?

Do analysts prefer TLX or ABVX?

Which has stronger earnings & valuation, TLX or ABVX?

Summary

How does Telix Pharmaceuticals compare to Krystal Biotech?

Do analysts recommend TLX or KRYS?

Is TLX or KRYS more profitable?

Which has preferable earnings & valuation, TLX or KRYS?

Does the media refer more to TLX or KRYS?

Which has more volatility & risk, TLX or KRYS?

Do insiders and institutionals have more ownership in TLX or KRYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools